Bioventus Earnings Call Highlights Growth, Cash Strength

Bioventus, Inc. ((BVS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Bioventus’ latest earnings call struck an upbeat tone, with management emphasizing broad-based momentum in revenue, profitability and cash generation. Executives acknowledged some one-time benefits and near-term noise, but stressed that stronger margins, rising cash flow and stepped-up investments in new growth platforms position the company for durable improvement.

Revenue Growth and Guidance Reaffirmed

Bioventus reported first-quarter revenue of $132.0 million, a 7% increase from a year earlier that showed steady demand across core franchises. Management kept its 2026 revenue outlook intact at $600 million to $610 million, signaling confidence that current trends and pipeline investments can sustain a mid-single-digit to high-single-digit growth profile.

Strong Adjusted EBITDA Expansion

Profitability moved faster than sales, with adjusted EBITDA rising 24% year over year to $24 million, roughly a $5 million gain. The adjusted EBITDA margin widened by 260 basis points to 18%, underscoring early returns from cost discipline and mix improvement even as the company begins to reinvest more aggressively.

Adjusted EPS Nearly Doubled and Guidance Raised

Earnings quality improved as adjusted EPS climbed to $0.15 in the quarter, nearly double the prior-year $0.08. On the back of that performance, Bioventus nudged its full-year adjusted EPS guidance higher to a range of $0.75 to $0.79, adding two cents to the prior outlook.

Improved Gross Margin and Profitability

The company’s adjusted gross margin reached 76%, up 110 basis points year over year helped by a favorable rebate adjustment and a refund of prior tariffs. Adjusted operating income increased to $20 million and adjusted net income to $13 million, representing roughly $3 million and $7 million gains respectively and marking a clear step-up in overall profitability.

Material Cash Flow and Balance Sheet Progress

Cash generation surprised positively, with $9 million in operating cash flow, about $28 million better than the prior-year quarter and the strongest first quarter since going public. Cash on hand stood at $36 million while total debt fell by $22 million to $272 million, and management reiterated its aim to push net leverage below two times by the end of the second quarter of 2026.

International and Segment Momentum

International markets were a bright spot as revenue grew 17% year over year, or 11% on a constant-currency basis, highlighting rising demand outside the U.S. Within segments, Pain Treatments advanced 8%, Surgical grew 6% and Restorative Therapies 5%, while Ultrasonics showed better traction in Europe and was flagged as an emerging growth engine.

Focused Investment in Growth Drivers and Leadership Hire

Bioventus is leaning into its newer platforms, planning about $13 million in incremental investment this year, with more than half directed to peripheral nerve stimulation. The company also hired Megan Rosengarten as General Manager for the PNS business, underscoring its intent to scale that franchise with focused leadership and dedicated resources.

Upgraded Cash From Operations Guidance

On the back of the strong start to the year, management raised its full-year cash from operations guidance to a range of $84 million to $89 million. The upgrade, which adds $2 million to the prior outlook, reflects confidence that improved earnings power and better working capital management can sustain stronger cash conversion.

One-Time Favorable Rebate Benefit

Executives cautioned that part of the Q1 outperformance stemmed from a one-time favorable rebate adjustment tied to a process change by a commercial payer. They stressed that similar rebate variability is not expected to recur and, as a result, chose not to lift revenue guidance solely on the back of this temporary boost.

Investment-Driven Expense Increases and Margin Volatility

As Bioventus accelerates spending behind PNS, PRP, Ultrasonics and international expansion, adjusted operating and R&D costs rose by about $5 million in the quarter. Management warned that margins could fluctuate from quarter to quarter as these investments ramp, even while targeting an adjusted EBITDA margin around 20% in 2026.

Surgical Growth Behind Near-Term Expectations

Global Surgical Solutions delivered 6% growth in the first quarter, a level the company had anticipated would be slower ahead of a planned ramp in the second half. Still, leadership acknowledged that the business is tracking somewhat below earlier internal expectations for early 2026, indicating a need for execution improvements to hit longer-term goals.

Inventory and Timing Headwinds in Pain Treatments

In Pain Treatments, management pointed to distributor inventory reductions and one fewer selling day as near-term headwinds, particularly in the hyaluronic acid portfolio. Adjusting for those factors and the rebate impact, leadership said operational growth in Pain would have landed in the mid-single-digit range, underscoring underlying demand resilience.

Outstanding Leverage Remains Material

Despite the progress on cash and debt reduction, Bioventus still carries $272 million of total debt, which remains a key balance-sheet consideration for investors. Management views deleveraging as a priority and reiterated that continued cash generation should support a steady march toward its sub-2.0 times net leverage target.

Early-Stage Growth Drivers with Ramp Time

PNS and platelet-rich plasma therapies are still in the early innings of commercialization, contributing modestly to current revenue but viewed as meaningful long-term drivers. Success will depend on ramping sales coverage, clinical support and surgeon training, particularly for Ultrasonics, so management framed their impact as building gradually over multiple quarters.

Guidance and Forward-Looking Outlook

Looking ahead to 2026, Bioventus reaffirmed revenue guidance of $600 million to $610 million while raising its adjusted EPS range to $0.75 to $0.79 and lifting expected cash from operations to $84 million to $89 million. The company aims to maintain roughly 20% adjusted EBITDA margins, drive faster growth in the second half versus the first and reduce net leverage below two times by the end of the second quarter of 2026.

Bioventus’ earnings call painted a picture of a company gaining traction, with improving margins, stronger cash flow and a clearer path to deleveraging balancing near-term volatility. For investors, the story hinges on management’s ability to translate stepped-up investment in PNS, PRP, Ultrasonics and international markets into sustained growth without losing the profitability gains now in hand.